Skip to content

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

The Safety and Effectiveness Study of Prebiotics and Probiotics in the Intervention of Obesity in Children With Prader-Willi Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05791604
Enrollment
60
Registered
2023-03-30
Start date
2023-04-01
Completion date
2029-07-31
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prader-Willi Syndrome

Keywords

Prader-Willi syndrome, Probiotics, Prebiotics

Brief summary

Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.

Detailed description

Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. Morbid obesity and related complications caused by hyperappetite are the most common causes of poor prognosis and death in PWS. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. At present, more and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children. Participants will be divided into three groups, receiving probiotics, probiotics+probiotics or placebo treatment, and observe the changes in body weight, the structure of gut microbiota and metabolic level.

Interventions

DIETARY_SUPPLEMENTprobiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG

Take probiotics, 2g each time, twice a day, for 12 weeks

DIETARY_SUPPLEMENTPrebiotics with galactomannan and oligofructose

Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks

Sponsors

Children's Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Pre-adolescent children with Prader Willi syndrome which were definitely diagnosed by gene testing. * Consistent with the diagnostic criteria for obesity. * Not participate in other research projects at present or three months before the research; * Agree to participate in the test and obtain the consent of their parents; voluntarily be the subjects and sign the informed consent form.

Exclusion criteria

* Losing weight in ways other than the intervention measures of this project, such as taking weight loss drugs or known drugs that cause weight change; * Use antibiotics within 1 month before the study and lasted for 3 days or more; * Use probiotics within 1 month before the study and lasted for 3 days or more; * Complicated with liver and renal insufficiency (alanine aminotransferase and serum creatinine indexes exceed 2 times the upper limit of the normal value set by the hospital); * Have gastrointestinal diseases affecting food digestion and absorption (such as severe diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcer, acute cholecystitis, etc.); severe diarrhea refers to watery stool 3 or more times a day and lasts for 3 or more days. severe constipation refers to defecation 2 or less times a week with difficulty in defecation; * Surgery was performed within 1 year before the study (except for appendicitis and hernia surgery); * Have hepatitis B, active tuberculosis, AIDS and other infectious diseases; * Those who are suffering from mental illness and are taking psychotropic drugs such as antidepressants.

Design outcomes

Primary

MeasureTime frameDescription
Body mass index12 weeksBody mass index is calculated as weight (kg)/\[Height (m)\^2\]. Weight and height will be combined to report BMI in kg/m\^2.

Secondary

MeasureTime frameDescription
Body composition4 weeks and 12 weeksBody composition including body fat percentage will be measured through body composition meter.
The structure of gut microbiota4 weeks and 12 weeksThe 16s rRNA genes of fecal samples were analyzed.
Height4 weeks and 12 weeksThe height is accurate to 0.1cm.
Weight4 weeks and 12 weeksThe weight is accurate to 0.1kg.
Waist circumference4 weeks and 12 weeksThe waist circumference is accurate to 0.1cm.
Glycosylated hemoglobin level4 weeks and 12 weeksThe glycosylated hemoglobin is accurate to 0.1%.
Fast triglyceride level4 weeks and 12 weeksThe fast triglyceride level will be measured by IMMULITE 1000 (Siemens,Germany).
Fast total cholesterol level4 weeks and 12 weeksThe fast total cholesterol level will be measured by IMMULITE 1000 (Siemens,Germany).
Fast low density lipoprotein level4 weeks and 12 weeksThe fast low density lipoprotein level will be measured by IMMULITE 1000 (Siemens,Germany).
Fast high density lipoprotein level4 weeks and 12 weeksThe fast high density lipoprotein level will be measured by IMMULITE 1000 (Siemens,Germany).
Defecation status4 weeks and 12 weeksCare givers describe the defecation status in the past 1 week, including the frequency, nature, and color.
Abdominal pain4 weeks and 12 weeksCare givers describe whether abdominal pain occurs, and if so, provide frequency.
Excessive flatulence4 weeks and 12 weeksCare givers describe whether excessive flatulence occurs, and if so, provide frequency.
Fast insulin level4 weeks and 12 weeksThe fast insulin level will be measured by IMMULITE 1000 (Siemens,Germany).
Fast glucose level4 weeks and 12 weeksThe fast glucose level is detected by fingertip blood with blood glucose meter.
Body mass index4 weeksBody mass index is calculated as weight (kg)/\[Height (m)\^2\]. Weight and height will be combined to report BMI in kg/m\^2.

Countries

China

Contacts

CONTACTWei Lu, Dr
wei_lu@fudan.edu.cn86-021-64933281
STUDY_DIRECTORWei Lu, Dr

Children's Hospitial of Fudan Univeristy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026